Specific \textit{p}53 Gene Mutations in Urinary Bladder Epithelium after the Chernobyl Accident\textsuperscript{1}

Shinji Yamamoto, Alina Romanenko, Min Wei, Chikayoshi Masuda, Wadim Zaparin, Vladmir Vinnichenko, Alexander Vozianov, Chyi Chia R. Lee, Keiichirou Morimura, Hideki Wanibuchi, Mitsuhiro Tada, and Shoji Fukushima\textsuperscript{2}

Department of Pathology, Osaka City University Medical School, Osaka 545-8585, Japan [S. Y., M. W., C. M., C. C. R. L., K. M., H. W., S. F.]; Departments of Pathology [A. R.] and Urology [W. Z., W. V., A. V.], Institute of Urology and Nephrology, Academy of Medical Sciences of Ukraine, Kiev 252053, Ukraine; and Laboratory for Molecular Brain Research, Hokkaido University School of Medicine, Sapporo 060-8638, Japan [M. T.]

\textbf{ABSTRACT}

After the Chernobyl accident, the incidence of urinary bladder cancers in the Ukraine population increased gradually from 26.2 to 36.1 per 100,000 between 1986 and 1996. Urinary bladder epithelium biopsied from 45 male patients with benign prostatic hyperplasia living in radiocontaminated areas of Ukraine demonstrated frequent severe urothelial dysplasia, carcinoma \textit{in situ}, and a single invasive transitional cell carcinoma, combined with irradiation cystitis in 42 cases (93%). No neoplastic changes (carcinoma \textit{in situ} or transitional cell carcinoma) were found in 10 patients from clean areas (areas without radiocontamination). DNA was extracted from the altered urothelium of selected paraffin-embedded specimens that showed obviously abnormal histology (3 cases) or intense \textit{p}53 immunoreactivity (15 cases), and mutational analysis of exons 5–8 of the \textit{p}53 gene was performed by PCR-single-strand conformational polymorphism analysis followed by DNA sequencing. Nine of 17 patients (53%) had one or more mutations in the altered urothelium. Urine sediment samples were also collected from the patients at 4–27 months after biopsy and analyzed by PCR-single-strand conformational polymorphism analysis or yeast functional assay, and identical or additional mutations found in these male patients may alert us to a future elevated occurrence of urinary bladder cancers in the radiocontaminated areas.

\textbf{INTRODUCTION}

Due to the Chernobyl Nuclear Power Plant accident in April 1986, more than 10 million people are currently living in radiocontaminated areas of Ukraine, Belarus, and Russia. They have been exposed for more than 12 years to low doses of ionizing radiation. \textsuperscript{137}Cs and, to a lesser extent, \textsuperscript{134}Cs constitute 80–90% of the incorporated radioactivity in people living in these areas, and these radionuclides are known to be concentrated and excreted in the urine (1). In the 11 years between 1986 and 1996, the incidence of urinary bladder cancer in the Ukraine population increased from 26.2 to 36.1 per 100,000 (2). A significant increase in childhood thyroid cancer was also observed in the Ukraine population increased from 26.2 to 36.1 per 100,000 between 1986 and 1996. Urinary bladder epithelium biopsied from 45 male patients with benign prostatic hyperplasia living in radiocontaminated areas of Ukraine demonstrated frequent severe urothelial dysplasia, carcinoma \textit{in situ}, and a single invasive transitional cell carcinoma, combined with irradiation cystitis in 42 cases (93%). No neoplastic changes (carcinoma \textit{in situ} or transitional cell carcinoma) were found in 10 patients from clean areas (areas without radiocontamination). DNA was extracted from the altered urothelium of selected paraffin-embedded specimens that showed obviously abnormal histology (3 cases) or intense \textit{p}53 immunoreactivity (15 cases), and mutational analysis of exons 5–8 of the \textit{p}53 gene was performed by PCR-single-strand conformational polymorphism analysis followed by DNA sequencing. Nine of 17 patients (53%) had one or more mutations in the altered urothelium. Urine sediment samples were also collected from the patients at 4–27 months after biopsy and analyzed by PCR-single-strand conformational polymorphism analysis or yeast functional assay, and identical or additional \textit{p}53 mutations were found in four of five cases. Interestingly, a relative hot spot at codon 245 was found in five of nine (56%) cases with mutations, and 11 of the 13 mutations determined (73%) were G:C to A:T transitions at CpG dinucleotides, reported to be infrequent (1–18%) in human urinary bladder cancers. Therefore, the frequent and specific \textit{p}53 mutations found in these male patients may alert us to a future elevated occurrence of urinary bladder cancers in the radiocontaminated areas.

\textbf{MATERIALS AND METHODS}

\textbf{Patients.} The subjects were 55 male patients (49–92 years old) undergoing surgery for BPH at the Institute of Urology and Nephrology, Academy of Medical Sciences of Ukraine (Kiev, Ukraine) between 1994 and 1997. All 55 patients received multiple mapping biopsies of the urinary bladder mucosa during the operation for BPH. The group I patients (28 of 55 patients; average age, 62 years) had been continuously inhabiting radiocontaminated areas of Ukraine with the density of \textsuperscript{137}Cs contamination of \( \geq 30 \) Ci/km\(^2\), and group II patients (27 of 55 patients; average age, 75 years) were from Kiev city (\textsuperscript{137}Cs contamination, 0.5–5 Ci/km\(^2\); Ref. 14). The group III controls were 10 patients (average age, 66 years) living in so-called “clean” areas of the country (areas without radiocontamination; Ref. 14). Although detailed information was not available, the majority of patients had smoked for more than 20 years (about 20 cigarettes/day).

\textbf{Histological Examination.} Formalin-fixed, paraffin-embedded tissue blocks were routinely processed, sectioned, and stained with H&E for histological examination. Before molecular analysis, all urothelial lesions (severe dysplasia, CIS, or small invasive TCC) were immunohistochemically investigated with an anti-p53 antibody (DO-7; DAKO, Glostrup, Denmark; Ref. 15) and assessed as described previously (12).

\textbf{DNA Preparation.} Urinary bladder epithelial lesions with intense \textit{p}53 nuclear immunoreactivity (>10% of cells stained) or without positivity for \textit{p}53 but with histological abnormalities (severe dysplasia, CIS, or TCC) were

\textsuperscript{1}To whom requests for reprints should be addressed, at the Department of Pathology, Osaka City University Medical School, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Phone: 81-6-6645-3735; Fax: 81-6-6646-3093; E-mail: fukuchan@med.osaka-cu.ac.jp.

\textsuperscript{2}The abbreviations used are: CIS, carcinoma \textit{in situ}; TCC, transitional cell carcinoma; BPH, benign prostatic hyperplasia; SSCP, single-strand conformational polymorphism.
selected for DNA extraction. DNA for PCR was prepared from paraffin-embedded sections using a microdissection approach, as described previously (16). Briefly, serial sections adjacent to those used for histological analysis were prepared at a thickness of 3–7 μm, deparaffinized, and air-dried. Using a fine needle, selected epithelial lesions (length, 3–8 mm) were dissected out under a microscope. Tissues were collected in 20–100 μl of protein lysis buffer containing 0.1 mg/ml protease K. After adequate digestion, protease K was inactivated by boiling, and samples were diluted to an optimized concentration for PCR. For the samples with sufficient tissue, a part of the solution after digestion with protease K underwent DNA extraction with a kit (Sepagene; Sankyo Junyaku Co., Tokyo, Japan). The resulting DNA pellets were diluted with distilled water for PCR. Finally, 21 samples from 15 patients of groups I and II were available for analysis.

**PCR-SSCP and Direct Sequencing.** For the mutational analysis of *p53* gene exons 5–8, PCR-SSCP analysis (17) and direct sequencing were performed using the procedures described previously (18), with minor modifications. Primer sequences used were as follows: (a) exon 5, 5'-TCCAACCTCTGTCCTCTTCCCT-3' and 5'-CA GCCCTTGTCCTCCACAG-3'; (b) exon 6, 5'-GGCTGTGATTCCTCACTGAT-3' and 5'-TGGAAGGCTGAAATGGC-3'; (c) exon 7, 5'-AGGC GAGGCTGGAACCTGCTCTCAGG-3' and 5'-TGACGAGGAGCAGGC-3'; and (d) exon 8, 5'-TTCCCTTACTGCTCTTGGT-3' and 5'-AGG GAGGCAACTGACCCG-3'. To eliminate nonspecific amplification, hot start PCR was applied using AmpliTaq Gold (Perkin-Elmer Cetus Instruments, Norwalk, CT) according to the manufacturer’s instructions. PCR including [32P]dCTP for SSCP analysis was carried out under the following conditions: initial preheating at 96°C for 10 min to achieve enzymatic activity; followed by 38 reaction cycles (96°C for 30 s, annealing temperature varied between 54°C and 58°C for 30 s and 72°C for 30 s) and a final elongation (72°C for 12 min). In all cases with mutation, PCR-SSCP analysis was repeated at least once using independent PCR products, and the existence of a mutation was confirmed by direct sequencing. Throughout the experiment, special care was taken to avoid contamination of template DNA. PCR reagents were kept physically separated from the areas where PCR products were handled, and reagents were mixed in a COY Template Tamer hood (COY Co., Grass Lake, MI) equipped with UV light. For some cases with mutations, corresponding normal prostate or lymphatic tissues were included for analysis to test the presence of constitutional polymorphisms and germ-line mutations.

**Assessment of Urine Samples.** At 4–26 months after the biopsy, urine sediments were collected from six patients as described by Sidransky et al. (8), immediately frozen, and stored until use. Nucleic acids were extracted from pellets using Isogen (Nippon Gene, Toyama, Japan); the DNA layer was then further treated with Sepagene (Sankyo Junyaku). Sufficient amounts of RNA were obtained from two cases (cases 6 and 17) and used for *p53* yeast functional assays as described previously (13). DNA of urine sediment was available for three cases (cases 12, 14, and 15) and analyzed by PCR-SSCP as described above.

**Statistical Analysis.** Differences in the proportions of mutation patterns were examined for statistical significance with the χ² test.

**RESULTS**

In groups I and II, all cases exhibited proliferative cystitis, i.e., von Brunn’s nests, cystitis cystica, and squamous and glandular metaplasias, that were frequently combined and had features of irradiation...
cystitis rather than simple inflammation. Multiple areas of severe
dysplasia were detected in 42 of 45 (93%) patients, and 22 of 45
patients (49%) demonstrated areas of CIS. On the other hand, no
neoplastic changes were found in the group III urothelium, although
mild inflammation was evident within both the urothelium and sub-
mucosal tissues. Details of the immunohistochemical analysis of these
urothelial lesions have been reported elsewhere (12). DNA was ex-
tracted from the selected areas, and PCR-SSCP analysis was per-
formed on 21 samples from 15 cases. In addition, urine samples were
assessed by PCR-SSCP analysis (three cases) and yeast functional
assay (two cases). Overall mutational analyses were performed for 17
patients, with all but 3 patients (patients 1, 5, and 7) being intensively
positive for p53 immunohistochemistry.

Results of mutational analysis of the p53 gene are illustrated in Fig.
1. PCR-SSCP revealed that 9 of 17 cases (53%) harbored one or more
p53 mutations within identical or separate samples (Table 1). In three
cases (cases 13–15), identical mutations were found in separate sam-
ples, and a clonal relationship was strongly suggested. Considering
these mutations as single events, a total of 15 mutations were found in
nine cases. All p53 mutations determined were single-bp substitu-
tions, and no base deletions or insertions were found. All but one
mutation [case 16, codon 154; GGC (Gly) to GGT (Gly)] resulted in
amino acid changes. A total of 1 (6.7%), 4 (27%), 1 (6.7%), and 9
(60%) mutations were found in p53 exons 4, 5, 6, and 7, respectively,
and no mutation was found in exon 8. Eleven of 15 (73%) mutations
determined were G:C to A:T transitions at CpG dinucleotides, and
relative hot spots were noted involving three CpG dinucleotides
(codons 158, 245, and 248). Mutations at these sites have not been
reported to be frequent in human urinary bladder cancers (19, 20). In
the IARC database compiled by Hainaut et al. (20), G:C to A:T
transitions at CpG dinucleotides account for only 18.2% of the re-
ported 457 p53 mutations in urinary bladder tumors, demonstrating a
significant difference from our present data (χ² test, P < 3.5 × 10⁻⁹).
Because 9 of 15 mutations determined were concentrated between
codons 245 and 254 on exon 7, a primer pair was designed to include
this region [the upstream primer (5'-ACTACATGTTAACAGT-
TCC-3') and downstream primer (5'-TCTGACCTGAGTCT-
TCCA-3') produce an 86-bp short PCR fragment], and PCR-SSCP
analysis was performed for the DNAs extracted from the urothelium
of nine patients living in clean areas (group III). No abnormal band-
shifts were found.

In two cases (cases 14 and 15), mutations determined in the biopsy
samples were also found in the subsequent urine sediments by PCR-
SSCP analysis, suggesting the presence of mutated clones in the
urothelium and the exfoliation of significant numbers of altered cells
into the urine. In cases 6 and 17, p53 yeast functional assays of urine
samples gave 4% and 29% red colonies (Fig. 1c), respectively, and
more than four red yeast colonies were randomly selected and se-
quenced in both cases. In case 6, no identical mutation was found;
therefore, this case was considered negative for clonal mutation. A
pair of tandem mutations was evident in case 17 (codons 125 and 211
on the same cDNA fragment), clonal in 4 of 5 colonies.

**DISCUSSION**

In the present study, mutational analysis of the p53 gene in DNA
extracted from the urothelium of patients living in radiocontaminated
areas of Ukraine revealed that 9 of 17 cases (53%) harbored one or more
mutations within identical or separated samples (Table 1). This
frequency is similar to those described for human high-grade, invasive
urinary bladder cancers (9, 11). Although base deletions or insertions
of the p53 gene have been found in a certain proportion of human
urinary bladder cancers (19), all p53 mutations identified in this study
were single-bp substitutions. The most striking feature is the predom-
inance of G:C to A:T transition mutations at CpG dinucleotides,
especially on codons 158, 245, and 248. Although ionizing radiation
has been reported to cause a variety of types of DNA damage
including strand breaks and cross-linking (21), direct in vivo evidence

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age (yr)/group</th>
<th>Date of samplinga</th>
<th>Sample</th>
<th>Histology</th>
<th>Exon</th>
<th>p53 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57/I</td>
<td>Feb. 1997</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>69/I</td>
<td>May 1996</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>60/I</td>
<td>May 1995</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>4</td>
<td>74/I</td>
<td>Nov. 1996</td>
<td>Biopsy</td>
<td>CIS</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>67/I</td>
<td>Mar. 1996</td>
<td>Biopsy</td>
<td>CIS</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>6</td>
<td>78/I</td>
<td>May 1996</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>NE</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>69/I</td>
<td>Dec. 1994</td>
<td>Urine (yeast)</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>68/I</td>
<td>July 1996</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>66/I</td>
<td>Nov. 1994</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>63/I</td>
<td>Jan. 1995</td>
<td>Biopsy</td>
<td>CIS</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>11</td>
<td>73/I</td>
<td>Feb. 1997</td>
<td>Biopsy</td>
<td>Invasive TCC</td>
<td>5</td>
<td>251 ATC→CTC Ile→Leu A→C</td>
</tr>
<tr>
<td>12</td>
<td>68/I</td>
<td>May 1995</td>
<td>Biopsy</td>
<td>CIS</td>
<td>NE</td>
<td>None</td>
</tr>
<tr>
<td>13</td>
<td>66/I</td>
<td>Mar. 1995</td>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>14</td>
<td>63/I</td>
<td>Jan. 1997</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>15</td>
<td>68/I</td>
<td>July 1996</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>16</td>
<td>69/I</td>
<td>Feb. 1997</td>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>17</td>
<td>70/I</td>
<td>May 1995</td>
<td>Biopsy</td>
<td>CIS</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

Table 1 Mutational analysis of the p53 gene in urothelial lesions in male patients living in radiocontaminated areas of Ukraine

<table>
<thead>
<tr>
<th>Sample</th>
<th>Histology</th>
<th>Exon</th>
<th>Codon</th>
<th>Base change</th>
<th>Amino acid change</th>
<th>Substitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>251</td>
<td>ATC→CTC</td>
<td>Ile→Leu</td>
<td>A→C</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>245</td>
<td>GCC→AGC</td>
<td>Gly→Ser</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>158</td>
<td>CGC→CAC</td>
<td>Arg→His</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>175</td>
<td>CGC→TGC</td>
<td>Arg→Cys</td>
<td>C→T/CpG</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>245</td>
<td>GCC→AGC</td>
<td>Gly→Ser</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>245</td>
<td>GCC→AGC</td>
<td>Gly→Ser</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>245</td>
<td>GCC→AGC</td>
<td>Gly→Ser</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>245</td>
<td>GCC→AGC</td>
<td>Gly→Ser</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>245</td>
<td>GCC→AGC</td>
<td>Gly→Ser</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>7</td>
<td>ACT→ACC</td>
<td>Ile→Thr</td>
<td>T→C</td>
</tr>
<tr>
<td>Biopsy</td>
<td>Dysplasia</td>
<td>None</td>
<td>248</td>
<td>CGG→TGG</td>
<td>Arg→Trp</td>
<td>C→T/CpG</td>
</tr>
<tr>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>158</td>
<td>CGC→CAC</td>
<td>Arg→His</td>
<td>G→A/CpG</td>
</tr>
<tr>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>248</td>
<td>CGG→TGG</td>
<td>Arg→Trp</td>
<td>C→T/CpG</td>
</tr>
<tr>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>249</td>
<td>AGC→ATG</td>
<td>Arg→Met</td>
<td>C→T/CpG</td>
</tr>
<tr>
<td>Urine (SSCP)</td>
<td>Dysplasia</td>
<td>None</td>
<td>249</td>
<td>ACT→ATT</td>
<td>Thr→Ile</td>
<td>C→T/CpG</td>
</tr>
</tbody>
</table>

*Feb., February; Nov., November; Mar., March; Dec., December; Jan., January; Aug., August.

Moderate to severe dysplasia.

NE, not evaluated because samples for PCR were not available.

Tandem mutations on the same allele.
of radiation-induced bp substitutions is lacking. Sikpi et al. (22) reported that the mutation frequencies of γ-irradiated (137Cs) plasmid DNA replicated in a human lymphoblastoid cell line were increased about 62-fold over background levels, although the percentage of G:C to A:T transition mutations was not affected. As for childhood thyroid cancers after the Chernobyl accident, p53 mutations have been shown to be infrequent, with no specific mutations apparent (5). However, ret rearrangement was found to be frequent (6). Thus the underlying mechanism might be different from that responsible for the specific mutations observed in this study. In human urinary bladder cancers, no specific bp substitution pattern for the p53 gene has hitherto been described, and there has been no pointer to any specific mutagen (7, 19, 20). On the other hand, mutational analysis of schistosomal urinary bladder cancer (endemic in Egypt) gave results that are very consistent with our findings; namely, a high proportion of bp changes in metachronous samples (case 17) indicate that a strong carcinogenic mechanism might be different from that responsible for the specific mutations observed in this study. Recently, a close relationship between chronic infection and cancer risk has been suggested, with the production of nitric oxide during inflammatory processes playing a role (24). It has been shown that nitric oxide can produce transitions at CpG dinucleotides by deamination of 5-methylcytosine (24). In addition, endogenous formation of urinary nitroso compounds leads to O6-alkylguanine formation and G:C to A:T transitions (23). To ascertain the specificity of p53 mutations observed in the present study, we compared the mutational spectrum of urinary bladder cancers of Egyptian patients before and after the Chernobyl accident as well as normal autopsy-derived urinary bladder mucosa. 4

Two techniques were used in the present study to determine the p53 gene mutations in urine samples: (a) PCR-SSCP analysis (17); and (b) p53 yeast functional assay (13). When the PCR-SSCP technique is used to analyze p53 mutations, significant amounts of mutated cells are necessary (usually at least 20% of the total). However, if we can determine clonal and characteristic mutations in several red colonies by the yeast functional assay, it will allow the use of urine samples. We are now collecting urine samples from the general population in radiocontaminated areas of Ukraine to further assess the applicability of these noninvasive techniques.

Of the nine cases with p53 mutations, two cases (cases 16 and 17) proved to have multiple p53 mutations in their urinary tract, as reported previously by Spruck et al. (11) and Goto et al. (25). Different p53 mutations in independent urothelial lesions (case 16) or in metachronous samples (case 17) indicate that a strong carcinogenic insult may have resulted in multiple transformation events in a large field of urothelium, as demonstrated previously in an animal model (16). The frequent (9 of 17 cases, 53%) p53 mutations of altered urinary bladder epithelium in patients who visited the hospital without symptoms of urinary bladder disease suggest that the prediction of induction of urinary bladder cancer may be possible. More precise and widely applicable screening tests are now required for the residents of radiocontaminated areas.

ACKNOWLEDGMENTS

We thank Dr. Yoshihisa Yano (Second Department of Biochemistry, Osaka City University Medical School, Osaka, Japan) for advice. We are grateful to Emi Kawakami, Kuniko Nishizawa, Mari Dokoh, and Satomi Katagiri for assistance with this experiment.

4 Unpublished data.

REFERENCES


Specific \textit{p53} Gene Mutations in Urinary Bladder Epithelium after the Chernobyl Accident

Shinji Yamamoto, Alina Romanenko, Min Wei, et al.


\textbf{Updated version} Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/59/15/3606

\textbf{Cited articles} This article cites 22 articles, 10 of which you can access for free at: http://cancerres.aacrjournals.org/content/59/15/3606.full.html#ref-list-1

\textbf{Citing articles} This article has been cited by 5 HighWire-hosted articles. Access the articles at: /content/59/15/3606.full.html#related-urls

\textbf{E-mail alerts} Sign up to receive free email-alerts related to this article or journal.

\textbf{Reprints and Subscriptions} To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

\textbf{Permissions} To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.